CA2058940A1 - Liposomes cibles et methodes de couplage liposome-proteine - Google Patents
Liposomes cibles et methodes de couplage liposome-proteineInfo
- Publication number
- CA2058940A1 CA2058940A1 CA2058940A CA2058940A CA2058940A1 CA 2058940 A1 CA2058940 A1 CA 2058940A1 CA 2058940 A CA2058940 A CA 2058940A CA 2058940 A CA2058940 A CA 2058940A CA 2058940 A1 CA2058940 A1 CA 2058940A1
- Authority
- CA
- Canada
- Prior art keywords
- present
- protein
- liposome
- relates
- conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne un procédé permettant de synthétiser un lipide réactif pur comprenant, par exemple, N-¢4-(p-maléimidophényle)-butyryle!phosphatidyléthanolamine (MPB-PE) ainsi que des compositions apparentées. Les compositions de l'invention sont utiles en tant qu'agents d'accouplement, et peuvent être incorporées dans des liposomes et ensuite accouplées à des protéines, des cofacteurs ainsi qu'un certain nombre d'autres molécules. Un procédé d'accouplement préféré est également décrit ainsi que des conjugués de protéines. L'invention concerne également un procédé général de production de conjugué dimensionné de protéines-liposomes présentant des temps de circulation sanguine améliorés. L'invention concerne par ailleurs des compositions de conjugués dimensionnés de protéines-liposomes, produites selon le procédé de l'invention. Les conjugués de protéines-liposomes de l'invention ont une taille située dans une plage allant d'environ 75nm à environ 200nm. Les liposomes de l'invention peuvent avoir un potentiel trans-membrane dans leurs membranes, et peuvent être déshydratés. De plus, la composition peut contenir des agents bioactifs ionisables tels que des agents antinéoplastiques, et peut être utilisée dans des analyses de diagnostics.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002296884A CA2296884C (fr) | 1989-06-23 | 1990-06-22 | Liposomes cibles et methodes de couplage liposome-proteine |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/370,650 US5059421A (en) | 1985-07-26 | 1989-06-23 | Preparation of targeted liposome systems of a defined size distribution |
US41277989A | 1989-09-26 | 1989-09-26 | |
US412,779 | 1989-09-26 | ||
US370,650 | 1989-09-26 | ||
PCT/US1990/003582 WO1991000289A2 (fr) | 1989-06-23 | 1990-06-22 | Liposomes cibles et procedes d'accouplement de liposomes-proteines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002296884A Division CA2296884C (fr) | 1989-06-23 | 1990-06-22 | Liposomes cibles et methodes de couplage liposome-proteine |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2058940A1 true CA2058940A1 (fr) | 1990-12-24 |
CA2058940C CA2058940C (fr) | 2000-05-09 |
Family
ID=27005032
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002296884A Expired - Fee Related CA2296884C (fr) | 1989-06-23 | 1990-06-22 | Liposomes cibles et methodes de couplage liposome-proteine |
CA002058940A Expired - Fee Related CA2058940C (fr) | 1989-06-23 | 1990-06-22 | Liposomes cibles et methodes de couplage liposome-proteine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002296884A Expired - Fee Related CA2296884C (fr) | 1989-06-23 | 1990-06-22 | Liposomes cibles et methodes de couplage liposome-proteine |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0478715B1 (fr) |
JP (1) | JP3032004B2 (fr) |
AT (1) | ATE136211T1 (fr) |
AU (1) | AU642149B2 (fr) |
CA (2) | CA2296884C (fr) |
DE (1) | DE69026380T2 (fr) |
DK (1) | DK0478715T3 (fr) |
ES (1) | ES2085920T3 (fr) |
WO (1) | WO1991000289A2 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030097604A (ko) * | 1992-07-13 | 2003-12-31 | 유카리언, 인코포레이티드 | 세포의 세포내 구획으로 지질화된 면역글로불린을전달하기 위한 조성물, 지질화된 단백질 및 지질화된 항체 |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
BR9609743A (pt) * | 1995-07-27 | 1999-03-02 | Genentech Inc | Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
JP3735921B2 (ja) * | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | GPIb・脂質複合体およびその用途 |
US8076312B2 (en) | 2000-01-10 | 2011-12-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Use of lipid conjugates in the treatment of disease |
US9040078B2 (en) | 2000-01-10 | 2015-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases of the nervous system |
US7608598B2 (en) | 2000-01-10 | 2009-10-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of conjunctivitis |
US8501701B2 (en) | 2000-01-10 | 2013-08-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Use of lipid conjugates in the treatment of disease |
US7811999B2 (en) | 2000-01-10 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Use of lipid conjugates in the treatment of diseases |
US7893226B2 (en) | 2004-09-29 | 2011-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Use of lipid conjugates in the treatment of diseases |
US8304395B2 (en) | 2000-01-10 | 2012-11-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Lipid conjugates in the treatment of disease |
US7141552B2 (en) * | 2000-01-10 | 2006-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
US8916539B2 (en) | 2000-01-10 | 2014-12-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
US7772196B2 (en) | 2000-01-10 | 2010-08-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
US20010051348A1 (en) | 2000-01-28 | 2001-12-13 | Lee Chee Wee | Novel ligands and methods for preparing same |
WO2001054731A2 (fr) * | 2000-01-28 | 2001-08-02 | National University Of Singapore | Nouveaux ligands et procedes de preparation correspondants |
US8883761B2 (en) | 2001-01-10 | 2014-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases associated with vasculature |
WO2003000291A1 (fr) * | 2001-06-22 | 2003-01-03 | Techno Network Shikoku Co., Ltd. | Vesicules lipidiques, processus de production de vesicules lipidiques et procede d'immobilisation de gene sur ces vesicules lipidiques |
TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
US8859524B2 (en) | 2005-11-17 | 2014-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Lipid conjugates in the treatment of chronic rhinosinusitis |
US8906882B2 (en) | 2005-11-17 | 2014-12-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Lipid conjugates in the treatment of allergic rhinitis |
CA2705785A1 (fr) | 2006-11-14 | 2008-05-22 | Saul Yedgar | Utilisation de conjugues lipidiques dans le traitement de maladies ou de troubles oculaires |
EP2429532A4 (fr) | 2009-05-11 | 2015-05-27 | Yissum Res Dev Co | Conjugués lipides/polymères, leur préparation et leurs utilisations |
JP2016529284A (ja) | 2013-08-27 | 2016-09-23 | ノースイースタン ユニバーシティ | ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4193983A (en) * | 1978-05-16 | 1980-03-18 | Syva Company | Labeled liposome particle compositions and immunoassays therewith |
US4588578A (en) * | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4743560A (en) * | 1984-03-26 | 1988-05-10 | Becton Dickinson And Company | Solid phase assay |
CH668554A5 (de) * | 1984-04-09 | 1989-01-13 | Sandoz Ag | Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung. |
US4721612A (en) * | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
CA1264668A (fr) * | 1984-06-20 | 1990-01-23 | Pieter R. Cullis | Techniques d'extrusion pour la production de liposomes |
CA1270198C (fr) * | 1984-08-08 | 1990-06-12 | Marcel B Bally | Encapsulation d'agents antineoplastiques dans des liposones |
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
WO1986004232A1 (fr) * | 1985-01-18 | 1986-07-31 | Cooper-Lipotech, Inc. | Composition liposomique |
US4885172A (en) * | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
-
1990
- 1990-06-22 AT AT90917873T patent/ATE136211T1/de not_active IP Right Cessation
- 1990-06-22 EP EP90917873A patent/EP0478715B1/fr not_active Expired - Lifetime
- 1990-06-22 ES ES90917873T patent/ES2085920T3/es not_active Expired - Lifetime
- 1990-06-22 AU AU59399/90A patent/AU642149B2/en not_active Ceased
- 1990-06-22 DK DK90917873.3T patent/DK0478715T3/da active
- 1990-06-22 DE DE69026380T patent/DE69026380T2/de not_active Expired - Fee Related
- 1990-06-22 JP JP2509624A patent/JP3032004B2/ja not_active Expired - Fee Related
- 1990-06-22 WO PCT/US1990/003582 patent/WO1991000289A2/fr active IP Right Grant
- 1990-06-22 CA CA002296884A patent/CA2296884C/fr not_active Expired - Fee Related
- 1990-06-22 CA CA002058940A patent/CA2058940C/fr not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU5939990A (en) | 1991-01-17 |
ES2085920T3 (es) | 1996-06-16 |
EP0478715B1 (fr) | 1996-04-03 |
CA2296884A1 (fr) | 1990-12-24 |
WO1991000289A2 (fr) | 1991-01-10 |
ATE136211T1 (de) | 1996-04-15 |
DE69026380D1 (de) | 1996-05-09 |
CA2058940C (fr) | 2000-05-09 |
WO1991000289A3 (fr) | 1991-04-04 |
JPH04506518A (ja) | 1992-11-12 |
AU642149B2 (en) | 1993-10-14 |
CA2296884C (fr) | 2001-01-23 |
DK0478715T3 (da) | 1996-08-05 |
JP3032004B2 (ja) | 2000-04-10 |
EP0478715A4 (en) | 1992-08-12 |
DE69026380T2 (de) | 1996-10-17 |
EP0478715A1 (fr) | 1992-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2058940A1 (fr) | Liposomes cibles et methodes de couplage liposome-proteine | |
HUT48455A (en) | Process for producing stabilized pharmaceutical compositions containing dipeptide derivatives | |
DE3775783D1 (de) | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. | |
ATE232109T1 (de) | Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung | |
ATE226430T1 (de) | Verfahren zur herstellung hydro-monobenzoporhyrin photosensibilisatoren enthaltender liposomen | |
CA2331936A1 (fr) | Proteines a mutation d'epitopes; procede de fabrication | |
CA2138925A1 (fr) | Methode pour la production de lipoproteines reconstituees | |
CA2179029A1 (fr) | Proteines de type herisson induisant une structure embryonnaire chez les vertebres | |
IL112585A (en) | N-terminally chemically modified G-CSF and analogs process for their preparation and pharmaceutical compositions containing them | |
CH676715A5 (fr) | ||
RU94042935A (ru) | Водорастворенные комплексы включения соединений бензотиофена с водорастворимыми циклодекстринами, способ их получения и фармацевтический состав | |
CA2058967A1 (fr) | Composition d'esters de cellulose et procede de fabrication | |
CA2042635A1 (fr) | Conjugues d'acides gras-surfactant pulmonaire | |
DE69332654T2 (de) | Fragmente eines oberflächenaktiven lungenproteins | |
WO1997014712A3 (fr) | Derives sulfamate de derives 1,3,5(10)-estratriene, procede de production correspondant et compositions pharmaceutiques renfermant ces composes | |
ATE128466T1 (de) | Verfahren zur herstellung von 2,7- diazabicyclo(3.3.0)octanen. | |
US5071585A (en) | Phosphoric acid ester, process for preparing the same, and detergent composition containing the same | |
AU5008785A (en) | Process for synthesising peptides | |
DE69115327T2 (de) | Peptidderivate mit amphiphatischen Eigenschaften, ihre Zwischenprodukte und Liposome sowie Filme, die diese Derivate enthalten | |
FI890825A0 (fi) | Polyamid-imidloesningar och foerfarande foer deras framstaellning. | |
JP4226324B2 (ja) | カルボン酸型脂質 | |
PL317258A1 (en) | Derivatives of aminosulphonic acids, their application in synthesising pseudopeptides and method of obtaining them | |
CA2150998A1 (fr) | Composes derives du glycerol et du betaine pour le conditionnement des tissus | |
RU94000064A (ru) | Новые 2-циано-3-гидроксипропенамиды, метод их получения и содержащие их фармацевтические композиции | |
BR9507135A (pt) | Composto uso do mesmo processo de preparação do mesmo composição farmacêutica e composição cosmética |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed | ||
MKLA | Lapsed |
Effective date: 20060622 |